Protocol Section List

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Protocol Section List
You are on Page 2513 of 2568:
2503 2504 2505 2506 2507 2508 2509 2510 2511 2512 2513 2514 2515 2516 2517 2518 2519 2520 2521 2522 2523

Protocol Sections: The Identification Through IPD Sharing Statement are Modules For This Protocol Section

NCTID Brief Title Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Oversight Description Conditions View
NCT00087074 CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00087061 Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00087048 Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00087035 Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00087022 Monoclonal Antibody Therapy Rencarex in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00087009 Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086996 S0356 Oxaliplatin 5-FU Radiation Therapy RT Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal GE Junction Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086983 Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086970 Ifosfamide With or Without O6-Benzylguanine in Treating Patients With Unresectable Metastatic Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086957 Gefitinib Trastuzumab and Docetaxel in Treating Patients With Metastatic Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086944 Oblimersen Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkins Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086931 Oxaliplatin Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086892 Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086879 Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086866 Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086840 CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086827 Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086801 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkins Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086775 Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086762 Mindfulness Relaxation Compared With Relaxing Music and Standard Symptom Management Education in Treating Patients Who Are Undergoing Chemotherapy For Newly Diagnosed Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086749 Effect of Tamoxifen on Breast Density in Premenopausal Women With Breast Cancer or High Risk for Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086736 Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone Bicalutamide Alone and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086723 In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086710 Study of Enfuvirtide in HIV-Positive Subjects Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086684 Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086671 Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis MS Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086658 Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes HES Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086645 Citalopram for Children With Autism and Repetitive Behavior STAART Study 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086632 Study of Ovarex Oregovomab MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086619 Parathyroid Hormone PTH for Osteoporosis in Postmenopausal Women Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086606 A Safety and Efficacy Study of Xolair in Peanut Allergy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086593 Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086580 Fludarabine Fludara Plus Alemtuzumab CAMPATH MabCampath vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia B-CLL Patients Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086567 Predictors of Relapse of Ovarian Peritoneal and Fallopian Tube Cancers Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086554 Collection of Specimens for Study of Inflammatory Bowel Disease Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086541 Daily-Dose Consensus Interferon and Ribavirin Efficacy of Combined Therapy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086528 Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086515 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus 0431-020COMPLETED Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086502 Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086489 CP-675206 In Patients With Advanced Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086476 Study of Megakaryocytes From Patients With Abnormal Platelet Vesicles Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086463 Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension PAH Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086450 Comparison of Two Treatments for Multivessel Coronary Artery Disease in Individuals With Diabetes FREEDOM Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086437 Pharmacogenetics of Hypertriglyceridemia in Hispanics Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086424 Epidemiology of Insulin Growth Factor IGF and Cardiovascular Events Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086411 Comparing Smoking Treatment Programs for Lighter Smokers - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086398 Psychotherapy Enhancement for Therapeutic Community TC Retention - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086385 Maintaining Nonsmoking Older Smokers - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086372 Long-term Follow-up of HIV Infected Patients Identified During Early Infection Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086359 Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086346 Study Evaluating of Calcineurin Inhibitor and Sirolimus Rapamune Treatment in Liver Transplant Recipients Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086333 FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086320 A Study of Effectiveness and Safety of Paliperidone Extended-release ER Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086307 Lexapro and Pramipexole and to Treat Major Depression Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086294 ACP-103 to Treat Parkinsons Disease Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086281 Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086268 Non-small Cell Lung Cancer Study US75 Z-PACT Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086255 Tiagabine for the Treatment of Cocaine Dependence - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086242 Telephone Counseling or Standard Care in Patients Who Have Completed Treatment for Stages I II or III Cervical Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086229 Absorption and Distribution of Glucosamine and Chondroitin Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086216 Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086203 Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia CLL Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086190 Study of Antidepressants in Parkinsons Disease Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086177 Vaginal Progesterone to Reduce the Risk of Another Preterm Birth Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086164 Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086151 Identifying Low-Risk Patients With Pulmonary Embolism Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086138 Depression in Alzheimers Disease-2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086125 Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies 8669-024COMPLETED Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086112 Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086099 Study Evaluating the Addition of Amifostine Ethyol to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086086 Subcutaneous SC Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure CHF Anemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086073 Parkinsons Research The Organized Genetics Initiative Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086060 Pain Management Techniques for Fibromyalgia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086047 Coping Skills Training for Adolescents With Fibromyalgia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086034 Study of Motexafin Gadolinium for the Treatment of Non-Hodgkins Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00086021 Acupuncture for the Treatment of Chronic Daily Headaches Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085995 Progression of Spinal Fusion in Ankylosing Spondylitis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085982 Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085969 Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085956 Effects of Arzoxifene on Bone Mass and the Uterus Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085943 KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085930 Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085917 Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085904 Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085891 Efficacy Safety of Quetiapine Fumarate SEROQUEL Placebo in the Treatment of Acutely Ill Patients With Schizophrenia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085878 Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085865 Serotonin Transporters in Alcoholism Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085852 US 10 mL Bronchoscopic Lung Volume Reduction BLVR Phase 1 Emphysema Study - Initial Formulation Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085839 Erlotinib vs Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer NSCLC and Eastern Cooperative Oncology Group ECOGPerformance Status PS 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085826 A Phase III Study of the Efficacy of TaxotereAptosyn Versus TaxoterePlacebo in Non-Small Cell Lung Cancer Patients Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085813 Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085800 Dietary Fiber and Cardiovascular Inflammatory Markers Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085787 A Study of ARRY-142886 in Patients With Advanced Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085774 Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085761 Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085748 Safety Study With Paliperidone ER Extended-Release ER Tablets in Geriatric Patients With Schizophrenia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085735 Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085722 Joint Injections for Osteoarthritic Knee Pain Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085709 S0106 Cytarabine and Daunorubicin w or wo Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085696 VELCADE Bortezomib With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085683 Herpes Virus-6 and Epilepsy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085670 Cytokine Gene Polymorphisms in Bone Marrow Failure Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085657 Brain Electrical Stimulation to Enhance Recovery After Stroke Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085644 Human Anti-tumor Necrosis Factor TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085631 Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085579 Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085566 Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085553 Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085540 FR901228 in Treating Patients With Recurrent High-Grade Gliomas Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085527 FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085501 S0342 Paclitaxel Carboplatin and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085488 Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085475 Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085462 Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085449 Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine Mycophenolate Mofetil and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085436 DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085423 Cyclophosphamide Fludarabine and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085410 Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085397 Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085384 PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial Peritoneal or Fallopian Tube Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085371 Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085358 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel Carboplatin and Paclitaxel in Treating Patients With Stage II Stage III or Stage IV Ovarian Epithelial Fallopian Tube or Primary Peritoneal Cavity Carcinoma Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085345 Melphalan Arsenic Trioxide and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085332 Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085306 Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085293 Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085280 Erlotinib in Treating Patients With Stage IIIB Stage IV or Recurrent Non-Small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085254 Cilengitide Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085228 Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma Cancer of the Prostate Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085202 Treatment of Patients With Newly Diagnosed Medulloblastoma Supratentorial Primitive Neuroectodermal Tumor or Atypical Teratoid Rhabdoid Tumor Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085189 Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085176 Neurobehavioral Complications in Children Who Were Previously Treated With Steroids and Intrathecal Therapy for Acute Lymphoblastic Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085163 Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma Cancer of the Colon Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085150 LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085124 Daunorubicin Hydrochloride Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085111 Bevacizumab in Treating Young Patients With Refractory Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085098 Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System CNS Germ Cell Tumor Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085059 Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex in Treating Patients With Metastatic Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00085020 GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2Neu Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084981 Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084942 Gemcitabine and Capecitabine in Treating Patients With Advanced andor Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084929 The National CT Colonography Trial Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084916 CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Myelodysplastic Syndromes or Chronic Myelogenous Leukemia in Blastic Phase Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084903 Fluorescence and Reflectance Spectroscopy During Colposcopy in Detecting Cervical Intraepithelial Neoplasia and Dysplasia in Healthy Participants With a History of Normal Pap Smears Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084890 Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma Cancer of the Cervix Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084877 Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084864 Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma Cancer of the Prostate Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084838 Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS ATRT Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084825 Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084812 Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084799 Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer SCLC Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084786 Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084773 Neoadjuvant Cetuximab Fluorouracil and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084747 Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084734 Docetaxel Capecitabine and Cisplatin in Treating Patients With Advanced Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084721 Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084708 Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084695 Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084682 Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084669 Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084656 Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084643 GTI-2040 Oxaliplatin and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084630 Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084617 Phase II Study of Oxaliplatin Irinotecan and Capecitabine in Advanced GastricGastroesophageal Junction Carcinoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084604 Irinotecan Cisplatin and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084591 Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084578 Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084565 Paclitaxel Topotecan and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084552 Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084539 Adjuvant Hypofractionated Intensity-Modulated Radiation Therapy With Incorporated Boost in Treating Patients With Early-Stage Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084526 Computed Tomography CT Scans Using CT-On-Rails to Pinpoint the Location of the Tumor in Treating Patients With Prostate Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084513 Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2Neu-Expressing Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084487 Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084461 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084448 Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084435 S0217 Adjuvant Cisplatin and Docetaxel After Complete Resection Stage III or IV Head and Neck Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084422 N2001-03 CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084409 Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084396 Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive andor Progesterone-Receptor Positive Stage II Stage IIIA or Stage IIIB Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084383 Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma Cancer of the Pancreas Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084370 Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084344 Effect of 4-Hydroxytamoxifen Gel on Breast Density Salivary Sex Steroids and Quality of Life in Premenopausal Women Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084318 Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084305 Analysis of Specimens From Individuals With Pulmonary Fibrosis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084292 Database for Stroke in Infants and Children the International Pediatric Stroke Study Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084279 CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C Nonresponders Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084266 Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus MRSA Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084253 Study of Boosted Atazanavir ATV Versus Non-boosted ATV in Naive Patients Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084240 Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated Symptomatic Falciparum Malaria In Southeast Asia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084227 Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084214 STA-4783Paclitaxel or Paclitaxel Alone in Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084201 Interactions Between Cranberry Juice and Antibiotics Used to Treat Urinary Tract Infections Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084188 HIVSTD Safer Sex Skills Groups for Women in Drug Treatment Programs - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084175 HIVSTD Safer Sex Skills Groups for Men in Drug Treatment Programs - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084162 Neurocardiac Control in Major Depression Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084149 Cyclosporine A in Combination With Abacavir Sulfate Lamivudine and Zidovudine and LopinavirRitonavir in HIV Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084136 Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive HIV Infected Persons in Resource-limited Settings Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084123 Healing Touch and Relaxation Therapies in Cervical Cancer Patients Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084110 Use of Complementary and Alternative Medicine Among Older Mexican Americans Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00084097 Omalizumab to Treat Eosinophilic Gastroenteritis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View